Google
DFTX — DEFINIUM THERAPEUTICS, INC. (Healthcare >> Biotechnology)
DFTX FAQ
What is DFTX's ROE?
DEFINIUM THERAPEUTICS, INC. reports a Return on Equity (ROE) of -85.19%.
What is DFTX's dividend yield?
DEFINIUM THERAPEUTICS, INC. offers a dividend yield of 0.00%.
What is DFTX's Deepscope Quality Score?
Deepscope rates DFTX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DFTX?
Deepscope's AI Timing Score for DFTX is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DFTX belong to?
DEFINIUM THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 23.55
Price
-1.04
(-4.23%)
Day Change
|
|
|---|
DFTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 23.55 |
| PBV / Sector |
9.23 / 4.63
|
| Earning Per Share | -2.17 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
42.87 M
GREAT
|
| Average 1W Daily Value |
61.01 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:22 |
| Symbol | DFTX |
| Name | DEFINIUM THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 109.07 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,572.89 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One World Trade Center, New York, NY, United States, 10007
Phone: 212 220 6633
Website: https://definiumtx.com
Employees: 105
Sector: Healthcare >> Biotechnology
Description: Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
